10 November 2023
10 November 2023
While AI’s impact on drug development and clinical trials is clear, proof of value and evidence is needed to solidify the reality.
Imfinzi is approved in the US, EU, Japan and other countries for metastatic biliary tract cancer and unresectable HCC.
The company expects final Phase III readouts and regulatory submissions in 2024.
SFA Therapeutics has also announced new bridge funding of $4.5m, which will allow the company to proceed to Phase II.
Commercial companies need to build trust and address medicine affordability questions while ensuring clinical trial diversity.
The investment from the European Innovation Council will help Acorai fund a clinical validation trial and regulatory submissions.
Real-world evidence aligns with a previous RCT, confirming the effectiveness of IDgenetix medication management test.
The trial is designed to assess the tolerability and safety of AX-158 versus placebo in plaque psoriasis patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
